Marker Therapeutics
MRKR
28 hedge funds and large institutions have $8.52M invested in Marker Therapeutics in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
8% more funds holding
Funds holding: 26 → 28 (+2)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0.01% less ownership
Funds ownership: 22.29% → 22.27% (-0.01%)
22% less capital invested
Capital invested by funds: $10.9M → $8.52M (-$2.37M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$64.7K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$30.6K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$9.61K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$105K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$17K |
| 3 |
Morgan Stanley
New York
|
-$13.8K |
| 4 |
BlackRock
New York
|
-$1.63K |
| 5 |
Renaissance Technologies
New York
|
-$1.31K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VCM
26
Versant Capital Management
Phoenix,
Arizona
| $65 | – | – | – |
|
27
Fidelity Investments
Boston,
Massachusetts
| $52 | – | – | – |
|
|
HNB
28
Huntington National Bank
Columbus,
Ohio
| – | -$385 | -70 | Closed |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$70 | -16 | -52% |
|
MRKR Hedge Fund Activity: Q1 2024 in Review
28 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q1 2024, worth a combined $8.52M — down 22% from $10.9M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MRKR positions and 1 closed out — a net gain of 2 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $64.7K. The largest seller was Wedbush Securities, cutting an estimated $105K.
- 28 institutional investors held Marker Therapeutics (MRKR) as of Q1 2024, up from 26 in Q4 2023.
- Funds reported $8.52M of Marker Therapeutics stock for Q1 2024, down 22% quarter-over-quarter.
- 3 funds opened new Marker Therapeutics positions in Q1 2024 and 1 closed out, a net change of +2 holders.
- The largest Marker Therapeutics buyer in Q1 2024 was Susquehanna International Group, an estimated $64.7K added.
- The largest Marker Therapeutics seller in Q1 2024 was Wedbush Securities, an estimated $105K sold.
Based on aggregated 13F filings for Q1 2024.